C5 Blocking Peptide
Cat# MBS9627011-5x1mg
Size : 5x1mg
Brand : MyBiosource
Contact local distributor :
Phone : +1 850 650 7790
C5 Blocking Peptide – The purity is >90%,tested by HPLC and MS. Purity
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS9627011Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the… More details
Product Overview
Online Datasheet in PDFProduct Name
C5, Blocking Peptide
Full Product Name
C5 Blocking Peptide
Product Gene Name
C5 blocking peptide
Product Synonym Names
Anaphylatoxin C5a analog; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; C5; C5a; CO5_HUMAN; Complement C5 alpha'' chain; Complement C5; Complement component C5; CPAMD4
Form/Format
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.
Purity/Purification
The purity is >90%,tested by HPLC and MS.
Preparation and Storage
Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.
Antibody/Peptide Pairs
C5 peptide (MBS9627011) is used for blocking the activity of C5 antibody (MBS9608299)
Molecular Weight
188,305 Da
OMIM
120900
Supply Chain Verification
Manufactured in a lab with traceable raw materials manufactured on site. Coordinated product portfolio of antibodies, pairs, conjugates, recombinant proteins, and immunoassay materials available, please inquire.
Notes
For phospho antibody, we provide phospho peptide (0.5mg) and non-phospho peptide (0.5mg)
ISO Certification
Manufactured in an ISO 9001:2015 Certified Laboratory.
Applications Tested/Suitable for C5 blocking peptide
Blocking/Control
Related Product Information for C5 blocking peptide
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (immunoblot) and immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or immunostaining performed with the neutralized antibody.
Other Notes
Small volumes of C5 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Searchable Terms for C5 purchase
MBS9627011 is a blocking peptide targeting C5.
Additional Details
NCBI/Uniprot data below describe general gene information for C5. It may not necessarily be applicable to this product.
UniProt Primary Accession #
UniProt Related Accession #
GenBank Nucleotide #
NCBI Official Full Name
complement C5 isoform 2
NCBI Official Synonym Full Names
complement component 5
NCBI Official Symbol
C5
NCBI Official Synonym Symbols
C5D; C5a; C5b; ECLZB; CPAMD4
UniProt Protein Name
Complement C5
UniProt Synonym Protein Names
C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4
Protein Family
Complement C5
UniProt Gene Name
C5
UniProt Synonym Gene Names
CPAMD4
UniProt Entry Name
CO5_HUMAN
NCBI Protein Information
complement C5
UniProt Comments for C5
C5: Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Defects in C5 are the cause of complement component 5 deficiency (C5D). A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. An association study of C5 haplotypes and genotypes in individuals with chronic hepatitis C virus infection shows that individuals homozygous for the C5_1 haplotype have a significantly higher stage of liver fibrosis than individuals carrying at least 1 other allele (PubMed:15995705).
Protein type: Secreted, signal peptide; Secreted
Chromosomal Location of Human Ortholog: 9q33-q34
Cellular Component: membrane attack complex; extracellular space; extracellular region
Molecular Function: protein binding; chemokine activity; endopeptidase inhibitor activity; receptor binding; C5a anaphylatoxin chemotactic receptor binding
Biological Process: activation of MAPK activity; positive regulation of chemotaxis; in utero embryonic development; cytolysis; complement activation, alternative pathway; chemotaxis; glucose homeostasis; leukocyte migration during inflammatory response; complement activation; cellular calcium ion homeostasis; G-protein coupled receptor protein signaling pathway; positive regulation of angiogenesis; cell surface receptor linked signal transduction; regulation of complement activation; response to stress; innate immune response; negative regulation of dopamine secretion; inflammatory response; complement activation, classical pathway
Disease: Complement Component 5 Deficiency; Eculizumab, Poor Response To
Show more Protein type: Secreted, signal peptide; Secreted
Chromosomal Location of Human Ortholog: 9q33-q34
Cellular Component: membrane attack complex; extracellular space; extracellular region
Molecular Function: protein binding; chemokine activity; endopeptidase inhibitor activity; receptor binding; C5a anaphylatoxin chemotactic receptor binding
Biological Process: activation of MAPK activity; positive regulation of chemotaxis; in utero embryonic development; cytolysis; complement activation, alternative pathway; chemotaxis; glucose homeostasis; leukocyte migration during inflammatory response; complement activation; cellular calcium ion homeostasis; G-protein coupled receptor protein signaling pathway; positive regulation of angiogenesis; cell surface receptor linked signal transduction; regulation of complement activation; response to stress; innate immune response; negative regulation of dopamine secretion; inflammatory response; complement activation, classical pathway
Disease: Complement Component 5 Deficiency; Eculizumab, Poor Response To
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with C5 blocking peptide
| Reference Product | PubMed Publications |
|---|---|
| C5AR1 blocking peptide | >23 publications with C5 and C5AR1 |
| C8A blocking peptide | >6 publications with C5 and C8A |
| GPR77 blocking peptide | >6 publications with C5 and GPR77 |
| C8B blocking peptide | >4 publications with C5 and C8B |
| C3AR1 blocking peptide | >2 publications with C5 and C3AR1 |
| CXCR7 blocking peptide | >1 publications with C5 and CXCR7 |
Pathways associated with C5 blocking peptide
| Products by Pathway | Pathway Diagram |
|---|---|
| Activation Of C3 And C5 Pathway antibodies | Activation Of C3 And C5 Pathway Diagram |
| Class A/1 (Rhodopsin-like Receptors) Pathway antibodies | Class A/1 (Rhodopsin-like Receptors) Pathway Diagram |
| Complement Activation, Classical Pathway antibodies | Complement Activation, Classical Pathway Diagram |
| Complement And Coagulation Cascades Pathway antibodies | Complement And Coagulation Cascades Pathway Diagram |
| Complement And Coagulation Cascades Pathway antibodies | Complement And Coagulation Cascades Pathway Diagram |
| Complement Cascade Pathway antibodies | Complement Cascade Pathway Diagram |
| G Alpha (i) Signalling Events Pathway antibodies | G Alpha (i) Signalling Events Pathway Diagram |
| GPCR Downstream Signaling Pathway antibodies | GPCR Downstream Signaling Pathway Diagram |
| GPCR Ligand Binding Pathway antibodies | GPCR Ligand Binding Pathway Diagram |
| Herpes Simplex Infection Pathway antibodies | Herpes Simplex Infection Pathway Diagram |
Diseases associated with C5 blocking peptide
| Disease Name | Pubmed Publications |
|---|---|
| Nervous System Diseases Antibodies | >2403 publications with C5 and Nervous System Diseases |
| Neurologic Manifestations Antibodies | >1014 publications with C5 and Neurologic Manifestations |
| Inflammation Antibodies | >762 publications with C5 and Inflammation |
| Cardiovascular Diseases Antibodies | >698 publications with C5 and Cardiovascular Diseases |
| Vascular Diseases Antibodies | >674 publications with C5 and Vascular Diseases |
| Kidney Diseases Antibodies | >476 publications with C5 and Kidney Diseases |
| Anemia Antibodies | >286 publications with C5 and Anemia |
| Immunologic Deficiency Syndromes Antibodies | >264 publications with C5 and Immunologic Deficiency Syndromes |
| Necrosis Antibodies | >233 publications with C5 and Necrosis |
| Heart Diseases Antibodies | >178 publications with C5 and Heart Diseases |
Organs/Tissues associated with C5 blocking peptide
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Bone Antibodies | >2309 publications with C5 and Bone |
| Muscle Antibodies | >1295 publications with C5 and Muscle |
| Brain Antibodies | >791 publications with C5 and Brain |
| Kidney Antibodies | >519 publications with C5 and Kidney |
| Lung Antibodies | >486 publications with C5 and Lung |
| Liver Antibodies | >468 publications with C5 and Liver |
| Spleen Antibodies | >172 publications with C5 and Spleen |
| Bone Marrow Antibodies | >136 publications with C5 and Bone Marrow |
| Intestine Antibodies | >124 publications with C5 and Intestine |
| Eye Antibodies | >119 publications with C5 and Eye |